Upfront Briefing
Novartis put a Phase 3 point on the board: remibrutinib posted positive topline results in chronic inducible urticaria, billed as the first therapy to achieve the primary endpoint in the condition.
Elsewhere, Moderna hit an Arbutus IP speed bump, while Immunic’s $200M private placement (with warrant upside) underscored that selective crossover appetite is still there. On the deal tape, Danaher’s $9.9B Masimo agreement kept healthcare M&A in the headlines.
Tape Action
| Instrument |
Last close |
1D % |
YTD % |
| S&P 500 |
6,843.2 |
+0.1% |
0.0% |
| Nasdaq 100 |
24,701.6 |
(0.1%) |
(2.2%) |
| Russell 2000 |
2,646.6 |
0.0% |
+6.6% |
| Healthcare (XLV) |
157.4 |
(0.2%) |
+1.7% |
| Biotech (XBI) |
124.6 |
+1.4% |
+2.2% |
| Nasdaq Biotech (NBI) |
5,970.5 |
+0.9% |
+4.6% |
| Clinical Trials (BBC) |
40.5 |
+1.6% |
+5.1% |
|
-
Biotech outperformed on an idiosyncratic-catalyst day: XBI (+1.4%) and NBI (+0.9%) finished solidly green even as the Nasdaq 100 ((0.1%)) faded.
-
Likely drivers: follow-through from clinical headlines (incl. Novartis remibrutinib, Compass Phase 3) plus continued “window open” sentiment in SMID biotech after a choppy macro tape.
-
Market data: U.S. close Tue 17-Feb-2026.
The Big 3
|
1
|
Novartis reports positive Phase III remibrutinib results
|
-
Novartis announced positive topline Phase III results for remibrutinib in chronic inducible urticaria, marking it as the first therapy to achieve the primary endpoint in this condition.
-
Why it matters:
This is meaningful lifecycle de-risking: Novartis is extending remibrutinib beyond CSU into chronic inducible urticaria, a sizeable population with limited targeted options. Importantly, Novartis says it has already filed an sNDA for symptomatic dermographism and plans broader global submissions — moving the story from “data” to “reg path,” which tightens timelines and raises probability-weighted value.
-
Source:
PR
|
|
2
|
Moderna faces setback in Arbutus mRNA patent dispute
|
-
Moderna suffered an adverse turn in its long-running mRNA/LNP patent dispute with Arbutus (and affiliates), a reminder that “platform” economics can be reshaped by IP outcomes even after commercialization.
-
Why it matters:
The investor issue isn’t near-term revenue — it’s the long-dated economics stack. Unfavorable IP rulings can increase expected royalty/damages exposure and add freedom-to-operate uncertainty across future mRNA products and partners, effectively raising the discount rate applied to the platform’s out-year cashflows.
-
Source:
Bloomberg Law
|
|
3
|
Immunic closes oversubscribed $200M private placement (up to $400M total)
|
-
Immunic closed an oversubscribed private placement financing for $200M upfront gross proceeds, plus warrants that could bring in up to an additional $200M (headline “up to $400M”).
-
Why it matters:
This is a balance-sheet reset with real signal: the round was led by BVF and included a heavyweight crossover syndicate (incl. OrbiMed, RA Capital, EcoR1, Vivo), which typically reflects higher conviction around upcoming execution. The trade-off is dilution + potential warrant overhang, but it materially extends runway and reduces near-term financing risk.
-
Source:
PR
|
Everything Else that broke
-
Compass rallies on second Phase III psilocybin win. —
BioCentury
-
Zealand Pharma reports positive Phase 1a ZP9830 results. —
PR
-
Ionis: early Tryngolza launch commentary (commercial traction + pipeline cadence into 2026). —
BioSpace
-
PitchBook: early-stage biotech felt the squeeze in 2025 as VC favored de-risked assets. —
BioSpace
-
Genmab initiates share buy-back program. —
PR
-
Q32 Bio announces $10.5M registered direct offering. —
PR
-
Bavarian Nordic wins $22.5M Canada mpox/smallpox vaccine deal. —
PR
-
Leo Pharma reports first profit in seven years. —
Endpoints
-
NovaBridge doses first patient in Phase 2 gastric cancer study. —
PR
-
Worldwide Clinical Trials completes acquisition of Catalyst Clinical Research. —
PR
-
Photocure reports Q4 2025 results. —
PR
-
Diakonos Oncology: DSMB recommends Phase 2 GBM study continue without modification. —
PR
Deal Flow
|
BioBucks 2026 Deal Trackers • Updated weekly
⬇️
|
M&A / BD&L
-
Danaher to acquire Masimo for $180/share (~$9.9B incl. debt; ~38% premium) — a notable healthcare capital deployment into monitoring/diagnostics comps. —
PR
(More:
Reuters)
-
CSL & Lilly sign clazakizumab licensing deal (IL-6 mAb; $100M upfront + milestones/royalties). —
PR
-
Bio Usawa, Nanoly Bioscience ink $500M licensing deal. —
PR
VC / Private Financings
-
Pharmacelera raises €6M — led by Heran Partners, joined by Clave Capital, Inveready and Bio&Tech Smart Capital. —
PR
IPOs / Follow-Ons
-
Immunic closes oversubscribed $200M private placement (up to $400M total). —
PR
-
HCW Biologics prices $1.5M at-the-market follow-on offering. —
PR
-
Coherus Oncology closes public stock offering (~$50.1M gross). —
PR
Academic Corner
- FDA go-ahead to test cellular rejuvenation therapy in humans. — Nature Biotech
- AI tool predicts over 1,000 diseases years before they happen — and more are on the way. — Nature Biotech
- Targeting the affective dimension of pain. — Nature Biotech
- Fecal microbiota transplantation plus pembrolizumab and axitinib in metastatic RCC (TACITO Phase 2a). — Nature Medicine
- Genomically matched therapy in advanced solid tumors (ROME trial). — Nature Medicine
- Microfluidic automation improves oocyte recovery from ovarian tissue. — Nature Medicine
|
